SHEPHERD VENTURES WHERE OTHERS CAN'T OR WON'T
SHEPHERD CAN MATCH ANY DRUG IN THE WORLD TO THE RARE CANCERS IN WHICH IT WILL WORK BEST
FIGHTING TOGETHER AGAINST RARE CANCERS
SHEPHERD actively pursues strategic partnerships with academic institutions, government agencies, patient foundations, and other bio-pharmaceutical companies who share our commitment to saving the lives of rare cancer patients.
As a private company exclusively focused on rare cancer, SHEPHERD can venture where other companies can’t due to competing demands on time, resources, bandwidth, and investor expectations.
SINCE ITS INCEPTION, SHEPHERD HAS:
IDENTIFIED EVERY FORM OF RARE CANCER BY ESTABLISHED CRITERIA
WORKED TO MAP THE MUTATIONAL AND DEVELOPMENT LANDSCAPE OF EVERY KNOWN FORM OF RARE CANCER
REVIEWED EVERY CLINICAL TRIAL CONDUCTED IN THE LAST 5 YEARS
MAPPED CLINICAL TRIAL SPENDING TO RARE VS. NON-RARE CANCERS
MAPPED ALL FDA-APPROVED TARGETED THERAPIES TO POTENTIALLY APPLICABLE PATIENT POPULATIONS
SHEPHERD aims to be the development partner of choice for rare and orphan indication development. Looking to expand the reach of your portfolio?